NeuBase Therapeutics, Inc.

SEC insider activity covers quarterly filings through June 30, 2026. Later filings are not included. Reported roles do not establish current employment or current holdings. SEC filing documents, sections and filing-text search cover filings dated January 1, 2000 onward. Earlier filings are deferred until after launch.

organization

SEC Insider

$3.0M

256 transactions

Summary

NeuBase Therapeutics, Inc. is an organization.

Recent Insider Transactions

As filed, including amendments; not net cash flow or current holdings. Joint reports count once. Totals cover known values only.

Buys: $1.7MSales: $712K24 insiders

Date	Insider	Type	Value
2023-09-08	Symetryx Corp	Sell	$197K
2023-09-14	Symetryx Corp	Sell	$186K
2023-09-07	Symetryx Corp	Sell	$135K
2023-09-15	Symetryx Corp	Sell	$130K
2023-09-01	Symetryx Corp	Buy	$60K
2023-09-18	Symetryx Corp	Sell	$60K
2023-09-11	Symetryx Corp	Sell	$5K
2023-08-02	Stephan Dietrich A(Founder and CEO)	M	$2K
2023-09-18	Joint reporting: Symetryx Corp; Shiff Barry; Shiff Aleta	J	$0
2023-08-02	Stephan Dietrich A(Founder and CEO)	M	$0
2023-03-16	Stephan Dietrich A(CEO and Director)	A	$0
2023-03-16	Branning Todd P.(Chief Financial Officer)	A	$0
2023-02-13	Stephan Dietrich A(President and CEO)	M	$0
2023-02-13	Stephan Dietrich A(President and CEO)	M	$0
2022-11-03	Branning Todd P.(Chief Financial Officer)	A	$0
2022-09-28	Stephan Dietrich A(CEO)	M	$0
2022-09-28	Stephan Dietrich A(CEO)	M	$0
2022-09-09	Ende Eric J	A	$0
2022-09-09	GOLDSTEIN DOV A MD	A	$0
2022-09-09	McDougall Gerald J	A	$0

SEC filings: SEC EDGAR

Activity data: SEC EDGAR

NeuBase Therapeutics, Inc. — Contributions, Lobbying & Contracts | Poliscope